Cenegermin

ApprovedProtein / enzyme

Cenegermin is one of 58 small molecule programs targeting Anterior Ischemic Optic Neuropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anterior Ischemic Optic NeuropathyActive, not recruiting

Eye DiseaseActive, not recruiting

KeratitisActive, not recruiting

Anterior Ischemic Optic NeuropathyPhase 3

Active, not recruiting

Eye DiseasePhase 3

Active, not recruiting

KeratitisApproved

Active, not recruiting

Competition

Competitive Landscape

200 competitors in Eye Disease

#DrugCompanyPhaseTrials

Neoral

Novartis

Phase 3

2 2

Bayer Aspirin

Bayer

Phase 3

1 3

Zovirax

BBp Consulting, Inc

Phase 3

2 4

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 5

Cenegermin

DDompé Farmaceutici S.p.A

Approved

1 6

Carboxymethylcellulose

AbbVie

Phase 3

4 7

Refresh Plus

AbbVie

Phase 3

1 8

ABBV-444

AbbVie

Phase 3

1 9

Oxervate

DDompé Farmaceutici S.p.A

Phase 3

1 10

EBI-005

EEleven Biotherapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Anterior Ischemic Optic Neuropathy

NCT07453888

Clinical

Trials by Indication[1]

Treatment1 trial

Corneal Nerves After Treatment With Cenegermin

Completed·UUniversity of California, Los Angeles··NCT04627571·8 enrolled

Keratitis1 trial

DOMPE -MT Neurotrophic Keratitis

Active, not recruiting·TToyos Clinic·Phase 4·NCT06947850·10 enrolled

Eye Disease1 trial

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

Completed·DDompé Farmaceutici S.p.A·Phase 3·NCT05136170·85 enrolled

Anterior Ischemic Optic Neuropathy1 trial

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Phase 3 Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Recruiting·DDompé Farmaceutici S.p.A·Phase 3·NCT07453888·272 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Cenegermin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cenegermin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cenegermin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dompé Farmaceutici S.p.A company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Approved[1]
Company: DDompé Farmaceutici S.p.A

Cenegermin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Treatment1 trial

Keratitis1 trial

Eye Disease1 trial

Anterior Ischemic Optic Neuropathy1 trial

References

Drug Info

Quick Facts

Related News